Request Trial
shutterstock_1231106194_pajor_pawel
Pajor Pawel / Shutterstock.com
1 February 2021Rory O'Neill

LSPN Connect: how COVID crystallised Oxford Uni’s licensing mission

The COVID-19 pandemic has brought into sharp relief the crucial role that universities play in cutting-edge innovation. One story of the past year is the collaboration between research institutions such as Oxford University, and commercial entities like AstraZeneca, to rapidly bring a life-saving product to market.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
Sanofi launches mRNA lawsuits on Moderna and Pfizer
15 July 2026   French drugmaker's Translate Bio unit accuses COVID rivals of infringing core lipid nanoparticle and mRNA purification patents, seeking damages from vaccines worth billions.
Pharma
UK-Switzerland strike trade deal with first-of-its-kind pharma rules
14 July 2026   An enhanced agreement between the two countries cements existing protections for pharma innovators and is being hailed by the industry as a boost for investment and research.
Careers
IP Federation elects Philips licensing leader as new president
14 July 2026   Kevin Scott will lead the organisation representing in-house counsel in the UK, for companies such as AstraZeneca, Eli Lilly, MSD and Regeneron.


Editor's picks

What’s at stake in Australia’s biggest pharma patent appeal in years?
Pharma
What’s at stake in Australia’s biggest pharma patent appeal in years?
1 July 2026

Editor's picks

Pharma
What’s at stake in Australia’s biggest pharma patent appeal in years?
1 July 2026
Biotech
Novartis and Eli Lilly sign separate $1.9bn novel drug deals
25 June 2026
Biotech
Insilico lands potential $2.5bn AI biotech partnership
22 June 2026
Pharma
US life sciences damages averaged $33.5m between 2019-2025
18 June 2026
Americas
Hikma v Amarin: Six takeaways from the pivotal ruling
9 June 2026
Americas
Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme
19 May 2026

More features

Sanofi launches mRNA lawsuits on Moderna and Pfizer
UK-Switzerland strike trade deal with first-of-its-kind pharma rules
IP Federation elects Philips licensing leader as new president
Interview: How BlueRock Therapeutics is layering IP in stem cell therapies
Explaining genetically engineered rodents to a jury—and ultimately beating Amgen
Exelixis opens two-front patent dispute over Cabometyx copies
UPC upholds injunction in Invisalign maker’s software dispute with rival
BioNTech and Pfizer secure big European win over mRNA patent